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1. Introduction 
Malignant melanoma is considered the most aggressive form of skin cancer. The incidence 
rate of the disease has steadily risen over the past few decades throughout the world. If 
melanoma is diagnosed early, it can be cured by surgical resection, but as soon as the first 
distant metastasis appears, the disease becomes one of the most aggressive types of 
metastatic, chemoresistant lesions. Cutaneous melanocytes originate from highly motile 
neural crest progenitors that migrate to the skin during embryonic development. They are 
pigment-producing skin cells that reside between keratinocytes in the basal layer of the 
epidermis, producing melanin in response to a variety of external stimuli, such as ultraviolet 
(UV) radiation. Although UV radiation is the main exogenous etiological risk factor for the 
development of the disease, other presently unknown factors are also involved. As 
estimated by the World Health Organization worldwide number of newly diagnosed skin 
cancer cases is between 2 and 3 million each year, of which 132,000 are melanoma. 
Additionally, in most western countries, the incidence of melanoma doubles roughly every 
decade. 
Malignant melanoma progresses through a series of well-defined clinical and 
histopathological stages, advancing in a stepwise manner from either a common acquired or 
a dysplastic nevus through the primary radial growth phase (RGP) and the vertical growth 
phase (VGP) to distant metastasis [Welch et al., 1997]. Different subtypes of the disease 
represent diverse entities, as there are marked differences in their biological behaviours. 
While the most common superficial spreading subtype (SSM) is characterised by a 
prolonged RGP, nodular melanoma (NM) begins to grow vertically from its onset. Clinical 
staging of primary cutaneous melanoma is based on measurements of tumour thickness (in 
millimetres), the presence or absence of ulceration, penetration through cutaneous layers, 
mitotic rate and evidence of lymph node, cutaneous or distant metastasis [Chin et al., 2006]. 
The vertical progression of lesions is representative of the degree of tumour progression and 
is measured by the Breslow thickness, which was first used in the early 1970s and measures 
the thickness of the tumour from the top of the epidermal granular layer (or from the ulcer 
base if the tumour is ulcerated) to the innermost depth of invasion. Ulceration of the tumour 
surface of melanoma covering the epidermis is one of the most sensitive parameters of 
metastatic potential. The currently used diagnostic and prognostic approaches to recognise 
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the disease at an early stage are based on morphological observations supplemented by 
sentinel lymph node biopsy, which can define the prognosis of melanoma and assist in 
choosing the optimal surgical treatment. However, despite the extensive research 
approaches that have been employed to study this disease, current prognostic biological 
markers, either alone or in combination, are not adequate for accurately performing 
individualised assessment of the predicted risk of melanoma progression and are often not 
helpful in defining the most effective therapy [Chin et al., 2006]. Similar to other solid 
tumours, it is assumed that the morphologic heterogeneity of melanoma originates from 
distinct genetic alterations that lead to diverse pathways of melanoma development and 
progression. To design effective therapeutic approaches, it is of critical importance to 
identify the genetic determinants of disease initiation and progression. Additionally, it is 
crucial to define the functionally important genetic/genomic alterations that result in 
melanoma initiation and progression [Ghosh & Chin, 2009]. Advances in genetic and 
genomic methodologies during the past decade have exponentially increased our 
understanding of the molecular genetic alterations associated with this disease. 
2. Molecular pathways involved in melanoma initiation and progression 
The genomic heterogeneity of melanoma and the complexity of the molecular pathways 
involved in disease development and progression suggest that no individual genetic or 
molecular alteration is crucial in these processes per se. The accumulation of and 
interactions between such alterations in combination with the interactions between the 
tumour cells and the microenvironment are involved in the generation of a specific set of 
biological outcomes [Palmieri et al., 2009].  
Current knowledge about the main molecular pathways at the DNA level and their 
interactions during melanomagenesis are summarised below. However, many other drivers 
of melanomagenesis remain to be discovered. 
2.1 Main genes involved in melanomagenesis and related signalling pathways 
2.1.1 CDKN2A and CDK4 in familial melanoma 
In addition to recognised heritable traits, such as skin, hair and eye colour, and the presence 
of a large number of nevi (benign, atypical or giant congenital), a familial history of 
melanoma (at least 3 affected relatives) is a significant risk factor for disease development 
[Chin et al., 2006; Sekulic et al., 2008]. Approximately 10% of individuals diagnosed with 
melanoma have a familial predisposition associated with a 2.24-fold increase in the risk of 
tumour development [Igbokwe & Lopez-Terrada, 2011]. Single-base mutations and 
deletions of the CDKN2A (cyclin-dependent kinase inhibitor 2A) gene at the 9p21 locus have 
been found to be the major germline alterations involved in these tumours, contributing to 
10% to 40% of familial melanoma cases. The penetrance of CDKN2A mutations appears to be 
influenced by geographical location [Meyle & Guldberg, 2009]. Other melanoma-prone 
families harbour mutations in different genes, including germline mutations in CDK4 
(cyclin-dependent kinase 4) or unidentified genes on chromosomes 1p22 and 20q11.22 
[Meyle & Guldberg, 2009; Sekulic et al., 2008]. 
CDKN2A encodes 2 overlapping, but distinct tumour-suppressor proteins, p16INK4a and 
p14ARF, utilising alternative promoters and first exons (1α for INK4a and 1ǃ for ARF) [Chin 
et al., 2006]. As most pathogenic mutations occur in exon 2 of these genes, they are often 
simultaneously altered in multiple tumours [Palmieri et al., 2009].  
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p16INK4a-CDK4/6-RB pathway 
RB1 (retinoblastoma 1) is an essential gatekeeper at the G1/S transition point of the cell 
cycle. In its underphosphorylated form, RB1 binds to the E2F transcription factor, 
preventing induction of the expression of genes crucial for the G1/S transition. However, 
when RB1 is phosphorylated by the activation of the CCND1 (cyclin D1) - CDK4/6 complex, 
E2F is released, leading the cell cycle to progress through the G1/S transition [Sekulic et al., 
2008]. The key regulatory molecule involved in this mechanism is p16INK4a, which inhibits 
the activity of CDK4/6 kinases in a dose-dependent manner and consequently causes cell 
cycle arrest [Chin et al., 2006]. Recently, it has been shown that p16INK4a functions as an 
alternate RB-independent regulator and suppressor of UV-induced DNA damage by 
reactive oxygen species and reduces the effect of oxidative stress in melanocytes via the p38 
stress-activated protein kinase [Jenkins et al., 2011]. 
Frequent point mutations in the coding region of the CDKN2A locus typically target and 
inactivate p16INK4a, while preserve p14ARF in 25% to 40% of melanoma-prone families and 
0.2% to 2% of sporadic melanomas [Chin et al., 2006; Meyle & Guldberg, 2009]. 
Additionally, CDKN2A appears to be homozygously deleted in approximately 50% of 
melanomas or silenced by promoter hypermethylation in 20% to 75% of tumours [Moore et 
al., 2008; Sekulic et al., 2008].  
Other members of the pathway rarely harbour mutations. Germline mutations in CDK4, an 
RB kinase inhibited by INK4a, have been only found in 15 melanoma-prone families [Meyle 
& Guldberg, 2009]. Most of these rare mutations target a conserved arginine residue at 
position 24 and substitute it with cysteine (R24C). Therefore, the mutant protein lacks the 
ability to bind to INK4a, but the CDK4-CCND1 interaction is preserved, resulting in the 
constitutive activation of this complex [Chin et al., 2006; Sekulic et al., 2008]. It is important 
to note that inactivating p16INK4a mutations and activating CDK4R24C mutations are not 
observed simultaneously, which suggests that they are mutually exclusive [Chin et al., 2006; 
Sekulic et al., 2008]. Alterations of CDK4 are also observed in sporadic melanomas (more 
commonly in the acral and mucosal types) in the form of focal gene amplification without 
p16INK4a deletion [Sekulic et al., 2008]. Other molecular alterations that are sometimes 
observed are CDK6 overexpression, rare mutations in CCND1 (approximately 4% of 
tumours) and inactivating mutations in RB1 in approximately 6% of sporadic melanomas, 
but germline mutation in RB1 is also observed, with an increased risk of tumour 
development [Sekulic et al., 2008]. 
p14ARF-MDM2-p53 pathway  
Inactivation of the p53 pathway is a common trait of cancers. The p53 protein is often 
referred to as the guardian of the genome because as a transcription factor, it regulates 
several genes involved in cell cycle arrest, senescence, DNA repair and apoptosis [Sekulic et 
al., 2008]. This broad set of functions entails precise control of the intracellular protein level 
by a complex network of positive and negative regulators. The main negative regulator is 
the MDM2 protein, which by binding to p53, promotes its ubiquitination and consequent 
proteosomal degradation. MDM2 is inhibited by p14ARF, which leads to the stabilisation of 
p53 [Sekulic et al., 2008]. Following DNA damage, p53 activates p21WAF1/CIP1, which blocks 
the CCNDE-CDK2 complex, causing cell cycle arrest at the G1/S transition point through 
the decreased phosphorylation of RB1, thus allowing DNA repair or apoptosis to occur 
[Sekulic et al., 2008]. 
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p53 is one of the most commonly mutated genes in human cancers. However, in contrast to 
most solid tumours, in which the pathway is inactivated at the level of p53 itself, point 
mutations in this gene are very rare in melanoma (occurring in approximately 9% of cases) 
and appear to rely on the inactivation of CDKN2A [Chin et al., 2006]. Although most 
mutations affect p16INK4a with or without p14ARF alterations, some melanoma-prone families 
exhibit mutations in p14ARF alone, which suggests that the loss of this gene itself could be 
sufficient for melanoma formation, and both p16INK4a and p14ARF are essential for melanoma 
suppression [Meyle & Guldberg, 2009; Sekulic et al., 2008]. Some data suggest that the 
tumour suppressor function of p14ARF might be fulfilled by other, unidentified p53-
independent mechanisms, which could also have important clinical implications [Sekulic et 
al., 2008]. 
2.1.2 Receptor tyrosine kinases (RTKs) 
RTKs are important targets of molecular alterations in various cancers. Although most of 
these changes occur at the expression level, several RTKs localise to regions affected by 
DNA copy number gains or amplifications [Chin et al., 2006]. In malignant melanoma, the 
most frequently altered RTKs are EGFR (epidermal growth factor receptor), c-MET (the 
oncogenic form of the hepatocyte growth factor receptor) and c-KIT (stem cell factor 
receptor) [Ghosh & Chin, 2009].  
EGFR (7p12) can be activated by EGF family ligands, such as EGF, TGF-α, amphiregulin or 
heparin-binding EGF [Ghosh & Chin, 2009]. Amplification, usually via copy number gains 
of the entire chromosome 7, and overexpression of EGFR have been frequently observed in 
late-stage melanomas and in association with the nodular subtype, which suggests that 
EGFR may support metastatic potential [Chin et al., 2006; Ghosh & Chin, 2009; Rother & 
Jones, 2009; Timar et al., 2010]. However, no focal EGFR amplification or mutation has been 
reported in melanoma [Chin et al., 2006; Ghosh & Chin, 2009]. Additionally, the EGFR 
signalling loop plays an important role in the RAS-driven tumourigenecity of melanoma 
cells. Animal models have suggested that autocrine EGFR signalling is essential for RAS-
mediated transformation by promoting survival through PI3K activation of AKT [Chin et 
al., 2006; Ghosh & Chin, 2009]. 
The c-MET receptor (7q31) is normally expressed on epithelial cells and melanocytes and is 
activated by its ligand, HGF (hepatocyte growth factor). Similar to EGFR, c-MET 
overexpression and copy number gains of the locus are late-stage events in tumour 
progression that contribute to the metastatic character of skin melanomas, but no focal gene 
amplification and/or activating mutations have been demonstrated [Chin et al., 2006; Ghosh 
& Chin, 2009; Timar et al., 2010]. Oncogenic c-MET activation mainly occurs in an autocrine 
manner with the establishment of a HGF-MET autocrine loop, which drives the 
development of metastatic disease rather than the initial steps of melanomagenesis [Chin et 
al., 2006; Ghosh & Chin, 2009]. Finally, it was recently shown that c-MET can be a direct 
target of microphthalmia-associated transcription factor (MITF), which can be itself 
amplified in a subset of melanomas [Chin et al., 2006; Ghosh & Chin, 2009]. 
The c-KIT gene (4q12) encodes an RTK that binds stem cell factor (SCF). Interestingly, c-KIT 
does not represent a typical RTK in malignant melanoma, as a progressive loss of its 
expression can frequently be observed during tumour progression. Furthermore, c-KIT-
expressing metastatic melanomas exhibit increased sensitivity to SCF-mediated apoptosis 
[Chin et al., 2006; Ghosh & Chin, 2009]. It has recently been reported that in some 
melanomas, c-KIT harbours a known GIST-associated point mutation, L576P, which maps to 
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the 5’ juxtamembrane domain, where most activating c-KIT mutations cluster [Chin et al., 
2006; Ghosh & Chin, 2009]. A recent analysis showed that approximately 21% of mucosal, 
11% of acral and 28% of melanoma developing on chronic sun-damaged skin exhibited an 
alteration in c-KIT. This suggests that the mutational and amplification status of c-KIT, 
which is usually mutually exclusive with BRAF and NRAS status, might have a significant 
clinical impact and may identify a patient subpopulation that would benefit from imatinib 
(c-KIT inhibitor) therapy [Ghosh & Chin, 2009; Igbokwe & Lopez-Terrada, 2011; Rother & 
Jones, 2009; Ko & Fisher, 2011].  
2.1.3 Main pathways involved in melanoma: RAS/MAPK and PI3K signalling 
Two major signalling cascades exist in melanoma: the RAS/MAP kinase pathway, which is 
mainly responsible for cellular proliferation, and the PI3 kinase pathway, which plays an 
important role in tumour cell survival. However, these regulatory functions are not 
exclusive, as interactions between the members of the two cascades enhance tumourigenesis, 
cell growth, chemoresistance, invasion, migration and cell cycle dysregulation [Sekulic et al., 
2008].  
2.1.3.1 RAS/MAPK pathway 
The RAS/MAPK signalling cascade is carried out through various RTKs, including FGFR, c-
KIT, c-MET or EGFR, and is strongly affected during tumourigenesis and progression. A 
receptor-ligand interaction initiates the phosphorylation cascade through RAS-RAF-MEK-
MAPK kinases and finally activates enzymes (involved in metabolic regulation), cytoskeletal 
components (affecting cell shape and migration) and specific transcription factors, such as 
ETS1/2, that are essential for the initiation of the expression of target genes related to cell 
proliferation and survival [Chin et al., 2006; Sekulic et al., 2008]. Hyperphosphorylated ERKs 
are common features of human cancers, including melanoma (approximately 90% of cases). 
This enforced activation is usually achieved through activating mutations related to 
upstream mediators, such as RAF and RAS [Chin et al., 2006; Igbokwe & Lopez-Terrada, 
2011; Palmieri et al., 2009].  
Activating mutations in the RAS proto-oncogene family (HRAS, NRAS and KRAS) are 
detected in melanoma with an incidence of between 10% and 15%. Point mutations in 
NRAS (Q61L) are the most common type of these mutations and are found in 56% of 
congenital nevi (but are rare in dysplastic and benign acquired nevi), as well as 33% of 
primary and 26% of metastatic melanomas correlated with a nodular subtype and 
intermittent sun exposure [Chin et al., 2006; Ghosh & Chin, 2009; Rother & Jones, 2009; 
Sekulic et al., 2008]. HRAS point mutations, together with genomic 11p amplifications, are 
rarely associated with melanomas. However, they are more frequent in Spitz nevi and 
indicate benign behaviour, whereas KRAS activations have not been observed in 
melanocytic lesions [Blokx et al., 2010; Chin et al., 2006; Ghosh & Chin, 2009]. Mouse models 
have revealed that RAS family members have distinct roles in melanocyte biology: HRAS 
mutations in combination with the inactivation of p16INK4a, p14ARF and/or p53 promote the 
development of nonmetastatic melanoma, whereas NRAS activations together with p16INK4a 
and p14ARF deficiencies cause cutaneous melanoma with a high penetrance and short latency 
[Chin et al., 2006; Ghosh & Chin, 2009]. 
The RAF proto-oncogene family consists of ARAF, BRAF and CRAF. Activating mutations in 
BRAF are the most widespread genetic alterations observed in human melanoma, with up 
to a 70% incidence, and they are associated with intermittent sun exposure and influence the 
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pattern of metastasis. In contrast, mutations in ARAF and CRAF have not been observed in 
human melanomas [Chin et al., 2006; Ghosh & Chin, 2009; Ko & Fisher, 2011; Meyle & 
Guldberg, 2009; Palmieri et al., 2009; Sekulic et al., 2008; Viros et al., 2008]. Among these 
point mutations, the most common is V600E (a valine to glutamic acid substitution), which 
accounts for >90% of all BRAF mutations [Meyle & Guldberg, 2009]. The BRAFV600E 
mutation is induced by UV damage, but its specific relationship with UV exposure has not 
yet been identified. It has recently been suggested that because MC1R variants are strongly 
associated with BRAF activation, they may modify the connection between BRAF mutation, 
nevus burden and melanoma risk, indicating that activating mutations for BRAF are 
somehow indirectly induced by UV radiation [Ko & Fisher, 2011; Palmieri et al., 2009]. BRAF 
mutations are common in nodular and superficial spreading melanomas arising in skin in 
association with intermittent sun exposure (59%), in contrast to the lentigo maligna 
melanomas that occur in chronically sun-exposed areas (11%) and acral (23%) and mucosal 
(11%) melanomas, and they are absent in uveal melanomas [Chin et al., 2006; Ghosh & Chin, 
2009; Rother & Jones, 2009]. Activating mutations are also seen in benign and dysplastic 
nevi, which often remain growth-arrested throughout an individual’s life time and rarely 
progress into melanoma, suggesting a role in the early neoplastic stages of melanoma and 
that there may be a BRAFV600E–induced checkpoint for malignant transformation [Chin et al., 
2006; Ghosh & Chin, 2009]. Congenital nevi are often positive for the senescence marker SA-
ǃ-Gal and for p16INK4a. In vitro studies have shown that in normal cells, BRAFV600E can 
induce p16INK4a, SA-ǃ-Gal and cell cycle arrest, resulting in oncogene-induced senescence 
[Chin et al., 2006; Ghosh & Chin, 2009; Palmieri et al., 2009]. However, p16INK4a positivity is 
not 100% correlated with SA-ǃ-Gal positivity, suggesting the presence of other factors 
involved in cell senescence, such as those regulated by IGFBP7 (IGF-binding protein 7). 
Benign nevi contain both BRAFV600E and high levels of IGFBP7, while BRAFV600E melanomas 
do not [Ghosh & Chin, 2009]. Additionally, BRAF can also cooperate with the p14ARF-
MDM2-p53 pathway because in p53-deficient zebrafish, mutant BRAF can induce invasive 
melanoma [Ko & Fisher, 2011; Palmieri et al., 2009]. 
BRAF and NRAS mutations are mutually exclusive at the single-cell level in melanoma, but 
they can be found in the same tumour with different segregation into neoplastic cells, 
potentially resulting in distinct biological properties and heterogeneous responses to 
therapy [Palmieri et al., 2007]. These alterations are also found in benign and dysplastic 
nevi, indicating that their activation is an early event in melanoma and is sufficient for 
initiation but is not involved in progression; therefore, additional genetic alterations are 
necessary for malignant transformation [Conway et al., 2010; Igbokwe & Lopez-Terrada, 
2011]. This exclusion may be based on the ability of melanoma cells carrying an NRAS 
mutation to bypass BRAF and signal via CRAF [Rother et al., 2009]. BRAF or NRAS 
mutations and concurrent genetic aberrations in BRAF and PTEN or MC1R are highly 
associated with intermittent sun exposure, whereas in acral melanomas or melanomas 
arising from chronic sun-exposed skin, wild-type BRAF and N-RAS can usually be found 
and are associated with copy number gains of CCND1 and CDK4, indicating the greater 
importance of the p16INK4a-RB cascade in these melanocytic lesions [Palmieri et al., 2007]. 
Finally, RAF-RAS mutations, possibly in association with mutant c-KIT and p16INK4a 
alterations, might be useful in distinguishing secondary new and metastatic melanomas, 
which could have considerable prognostic and clinical significance, as these melanomas are 
prone to systemic spread and are often incurable [Blokx et al., 2010].  
www.intechopen.com
 Genomics of Human Malignant Melanoma 
 
243 
2.1.3.2 PI3K/AKT pathway 
The PI3 kinase signalling cascade is activated by a number of extracellular signals in both 
paracrine and autocrine manners, such as signals from integrins, extracellular matrix 
proteins, HGF and insulin-like growth factors. This pathway is often hyperactive in 
melanoma and antagonises the intrinsic apoptotic pathway [Chin et al., 2006; Ghosh & Chin, 
2009; Sekulic et al., 2008]. Genetic alterations targeting members of the PI3K pathway are not 
as frequent as in the case of the RAS/MAPK pathway. PI3 kinase mutation occurs at a low 
frequency in melanoma (5%) [Palmieri et al., 2009]. The major genetic alteration observed is 
the deletion of PTEN (phosphatase and tensin homologue) at the 10q23 locus, which 
encodes a lipid and protein phosphatase. Loss of a PTEN allele or a change in its expression 
have been observed in approximately 20% and 40% of lesions, respectively; however, 
homozygous deletion and point mutations are rare in melanomas [Chin et al., 2006; Ghosh 
& Chin, 2009; Igbokwe & Lopez-Terrada, 2011; Timar et al., 2010]. As a negative regulator of 
the PI3 kinase pathway, PTEN reduces the intracellular level of PIP3 induced by PI3K and 
consequently blocks AKT activation and phosphorylation of the mTOR transcription factor, 
which promotes the expression of target genes involved in cellular division, cell migration 
and survival. Loss of PTEN may represent an essential aberration in the formation of 
invasive melanomas [Ko & Fisher, 2011]. 
Another important member of the PI3 kinase pathway is AKT, which exists in three 
isoforms: AKT1, AKT2 and AKT3. Although the complexity of this signalling pathway is not 
fully understood, it appears that the activation of different AKT isoforms may play distinct 
roles in tumour cell proliferation and survival and is associated with in situ melanomas and 
lesions arising from sun-exposed skin [Chin et al., 2006; Ghosh & Chin, 2009; Rother & 
Jones, 2009]. Following PIP3 formation, AKT becomes phosphorylated by PDK1 (pyruvate 
dehydrogenase kinase isozyme 1, mitochondrial) and consequently inactivates proapoptotic 
proteins, such as BAD, and activates the NFĸB and FOXO1 transcription factors, which 
promote the expression of genes involved in survival [Sekulic et al., 2008]. Constitutive 
activation of AKT3 through DNA copy number gains may be present in 40% to 60% of 
sporadic melanomas and stimulates a vertical growth phenotype, survival, migration, 
angiogenesis, glycolytic metabolism and cell cycle progression through the upregulation of 
CCND1 [Ghosh & Chin, 2009; Ko & Fisher, 2011; Palmieri et al., 2009; Sekulic et al., 2008]. 
However, it has been shown that AKT1 activation inhibits tumour cell migration and the 
invasion of particular cell lines, including melanomas [Chin et al., 2006; Ghosh & Chin, 
2009].  
PTEN can also regulate RAS/MAPK signalling and promotes cell cycle arrest at the G1/S 
transition point through the upregulation of p27KIP1. Moreover, activating mutant RAS can 
phosphorylate PI3K, resulting in increased AKT activity. Therefore, PTEN loss and the 
presence of oncogenic RAS are redundant [Rother & Jones, 2009; Sekulic et al., 2008]. 
2.1.4 Other important pathways in melanoma: WNT and MSH signalling 
2.1.4.1 WNT pathway 
WNT (wingless-type MMTV integration site family) signalling has significant developmental 
functions, especially in neural crest cells, such as melanocytes [Chin et al., 2006; Sekulic et 
al., 2008]. Activation of the canonical WNT pathway inactivates GSK3ǃ (glycogen synthase 
kinase 3 beta), which normally promotes the proteosomal degradation of ǃ-catenin via 
phosphorylation and results in an increased level of ǃ-catenin that enhances the expression 
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of target genes, such as MITF and CCND1, through activation of the TCF-LEF transcriptional 
complex [Chin et al., 2006; Sekulic et al., 2008]. Despite the frequent stabilising ǃ-catenin 
mutations that occur in melanoma cell lines, the incidence of these genetic alterations is 
much lower in primary melanoma samples. However, immunohistochemical studies have 
provided evidence of nuclear accumulation of ǃ-catenin, which reflects the activation of the 
canonical WNT pathway and the contribution of MITF as an important upstream regulator 
of melanoma survival/proliferation [Chin et al., 2006]. Overexpression of WNT5a is often 
observed in melanomas; nevertheless, its function is associated with protein kinase C 
activation rather than ǃ-catenin [Chin et al., 2006; Timar et al., 2010]. Furthermore, 
upregulation of WNT2 has also been found in melanomas, contributing to the inhibition of 
normal apoptotic progress, and determination of its protein level can be useful in 
distinguishing between melanoma and nevi [Palmieri et al., 2009]. 
2.1.4.2 MSH pathway 
MSH signalling is a key regulator of pigmentation through binding to its specific receptor, 
MC1R (melanocortin 1 receptor). MC1R, which is highly polymorphic, is expressed on 
epidermal melanocytes and determines the UV-induced skin response through modulating 
the induction efficiency of intracellular cAMP production [Chin et al., 2006; Meyle & 
Guldberg, 2009; Sekulic et al., 2008]. People with a red-hair-colour phenotype are unable to 
tan and exhibit more freckles; therefore, they display a 2.7 to 16.0-fold increase in risk of 
developing melanoma [Sekulic et al., 2008]. Some investigators have suggested that certain 
MC1R alleles have a pigment-independent effect on melanomagenesis [Chin et al., 2006; 
Meyle & Guldberg, 2009]. MSH-MC1R binding activates the canonical PKA (protein kinase 
A) response by inducing adenylate cyclase to produce cAMP, phosphorylates Rsk and/or 
PKA, which finally stimulate the CREB/ATF1 transcription factors. This complex both 
induces the expression of specific genes involved in pigmentation through direct regulation 
and activates the MITF promoter, which defines the tissue-specific expression of genes 
involved in pigmentation. The expression level of MITF affects the resulting phenotype; a 
low level defines pheomelanin, red-blond pigments, whereas a high level defines 
eumelanin, brown-black pigments [Chin et al., 2006]. In addition to PKA phosphorylation, 
activation of the RAS/MAPK pathway and inactivation of the PI3K pathway also appear to 
be consequences of cAMP stimulation. The general nature of cAMP and CREB/ATF1 
activation, compared to the highly tissue restricted nature of MITF activation, suggests the 
presence of a cooperating site that maps to the Sox10 consensus element in the MITF 
promoter [Chin et al., 2006].  
2.1.5 Novel pathways in melanoma: Notch1 and iNOS signalling  
2.1.5.1 Notch1 pathway 
The Notch signalling pathway plays key roles in tissue homeostasis and the regulation of 
cell fate [Bedogni & Powell, 2009]. Depending on cell-cell interactions and the extracellular 
environment, Notch can act as either a tumour suppressor or an oncogene [Palmieri et al., 
2009]. Upon activation, the Notch receptor undergoes two consecutive enzymatic cleavages, 
which result in the formation of NICD, a truncated variant of the receptor. NICD translocates 
to the nucleus and forms a complex with the CBF1 transcription factor and other co-
activators, which influences the intensity and duration of Notch signals and consequently 
induces transcription from promoters containing CBF1-responsive elements [Bedogni & 
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Powell, 2009; Palmieri et al., 2009]. Normally, Notch1 signalling induces growth arrest and 
differentiation in keratinocytes via p21WAF1/CIP1 induction and blocking WNT signalling. In 
melanomas and atypical nevi, Notch1 and 2 and their ligands are significantly upregulated. 
Notch1 exerts its effects through interactions with several pathways [Bedogni & Powell, 
2009; Palmieri et al., 2009]. Binding to ǃ-catenin mediates oncogenic activity either via the 
WNT pathway or by regulating N-cadherin. Notch1 also exhibits cross-talk with and 
inhibits the MAPK and PI3K pathways, contributing to the vertical growth phase. 
Furthermore, direct interactions between NICD and NFĸB cause the nuclear retention of 
NFĸB transcription factor and enhance melanoma cell survival (late Notch-dependent 
activation). NICD can also directly regulate IFNǄ expression by creating a complex with both 
NFĸB and IFNǄ promoters. Finally, RAS-mediated malignant transformation also requires 
intact Notch signalling [Palmieri et al., 2009]. Taken together, these data suggest that Notch 
may represent a novel target involved in melanomagenesis. 
2.1.5.2 iNOS pathway 
NO (nitric oxide) free radical production by NOS (nitric oxide synthase) plays an important 
role in immune responses. Three isoforms can be distinguished: nNOS/NOS I (neuronal) 
and eNOS/NOS III (endothelial) are constitutively expressed, and iNOS/NOS II (inducible) 
is transcriptionally regulated by several mediators [Palmieri et al., 2009]. In normal 
melanocytes, free radicals are completely inactivated via the redox function of eumelanin. 
Both reactive oxygen species (ROS) and reactive nitrogen species (RNS) have been identified 
in melanoma [Jenkins et al., 2011]. The effect of NO in tumour progression is dose 
dependent; a high NO concentration can lead to apoptosis via its effect on multiple 
apoptosis-related proteins, such as p53 and Bcl-2, and growth inhibition, whereas a low NO 
concentration may contribute to tumour growth and angiogenesis [Palmieri et al., 2009]. 
However, the role of iNOS in melanoma progression is still controversial. A higher level of 
iNOS has been found in subcutaneous and lymph node metastases of nonprogressive 
melanomas compared to that in progressive tumours, but the degree of iNOS expression is 
lower in metastases than in nevi or primary melanomas [Palmieri et al., 2009]. Finally, 
nNOS may also have an impact on melanomagenesis because approximately 82% of 
primary tumours, 72% of atypical nevi and 49% of benign nevi have been reported to 
express this protein, whereas normal melanocytes do not exhibit nNOS expression. 
Therefore, de novo expression of nNOS may be a marker for early stage tumours [Palmieri et 
al., 2009].  
Currently, the most effective therapy against melanoma is surgical resection of primary 
tumours, followed by observation of a sentinel lymph node [Gerami et al., 2009]. The 
cytogenetic heterogeneity of human melanomas results in significant problems in the 
classification of histologically ambiguous primary tumours and in differentiation between 
melanomas and other lesions, such as Spitz nevi, blue nevi or proliferating congenital nevi 
[Braun-Falco et al., 2009; Scolyer et al., 2010]. Understanding these alterations (Figure 1) and 
evaluating all of the known molecular targets in melanoma through the application of new 
molecular biological techniques, such as FISH, PCR, sequencing and microarrays, in 
addition to the gold standard of histopathologic examination, will be crucial in predicting 
subsets of patients with particular biological and clinical characteristics who may respond 
favourably to a therapy that specifically targets a characteristic molecular signature [Gerami 
et al., 2009; Ghosh & Chin, 2009; Palmieri et al., 2007].  
www.intechopen.com
 Breakthroughs in Melanoma Research 
 
246 
 
Fig. 1. Schematic representation of the signalling pathways affected in melanoma progression. 
Members showed (epi)genetic and/or expressional alterations are highlighted with blue 
3. Genetic alterations in malignant melanoma 
Molecular biological techniques developed during the last two decades have greatly 
improved our understanding of the genetic background of malignant melanoma. A number 
of studies using classical chromosome banding, fluorescence in situ hybridisation (FISH) and 
chromosomal and array comparative genomic hybridisation (CGH) have been performed to 
define the genetic alterations that underlie the development and progression of melanoma 
[Trent et al., 1991; Bastian et al., 1998; Chin et al., 2006]. These studies have identified a large 
number of non-random alterations on chromosomes 1p, 6, 7, 8q, 9, 10q, 11q and 17, the 
frequencies of which are reflective of the malignant potential of the sporadic form of the 
disease. As a result of detailed analysis, a number of tumour suppressors and oncogenes 
have been implicated as key factors in melanoma pathogenesis, including CDKN2A, PTEN, 
BRAF, NRAS, MITF, AIM1, CCND1, and MYC [Poetch et al., 2003; Casarso et al., 2005; 
Rákosy et al., 2008; Lázár et al., 2009; Dalton et al. 2010].  
3.1 Non-random copy number alterations  
Comparative genomic hybridisation represents the best approach for searching for DNA 
sequence copy number alterations in cancer genomes. Improvement of the resolution and 
sensitivity of CGH during the last decade has allowed the discovery of recurrent copy 
number alterations and new genetic targets in different cancer types, including malignant 
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melanoma. Although chromosomal and array CGH have revealed a large number of 
common non-random alterations (DNA sequence amplifications and deletions, Figure 2), no 
obvious or validated melanoma-relevant molecular targets have yet been identified [Gosh & 
Chin, 2009]. The non-random nature of melanoma-specific copy number alterations may 
allow the segregation of melanomas into subtypes based on distinct clinical and biological 
behaviours. The array CGH investigation of primary melanoma producing the greatest 
number of findings was reported by Curtin et al. [Curtin et al., 2005]. At the beginning of 
this study, it was hypothesised that the clinical heterogeneity of the disease could be 
explained by genetically distinct types of melanomas with different susceptibilities to 
ultraviolet light. 
 
 
Fig. 2. Array CGH profiles of malignant melanoma. A.) Control sample without copy 
number alteration. B.) Array CGH profile of a primary malignant melanoma sample. C.) 
melanoma metastasis 
Chromosome copy number alterations and the mutational status of the BRAF and NRAS 
genes were compared in 126 primary melanomas, and melanoma tissue samples were 
grouped based on their degree of exposure to ultraviolet light. The four types of melanoma 
included in these groupings were as follows: acral melanoma (melanoma occurring on the 
non-hair-bearing skin of the palms or soles), mucosal melanoma (tumours arising on 
mucosal membranes), tumours arising from skin with chronic sun-induced damage and 
lesions arising from skin without chronic sun-induced damage. Melanomas without chronic 
sun-induced damage frequently showed mutations in the BRAF oncogene, together with 
losses of chromosome 10q (site of PTEN), or mutations in the NRAS gene alone. In contrast, 
melanomas arising from skin with chronic sun-induced damage (mucosal and acral 
melanomas) did not exhibit BRAF or NRAS mutations but instead displayed an increased 
number of copies of the CCND1 or CDK4 genes. The different genetic alterations were 
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identified in different anatomical sites of the skin and with varying levels of ultraviolet 
exposure indicate that distinct molecular pathways are involved in the development and 
progression of the disease [Curtin et al., 2005].   
3.1.1 Genetic differences between benign and malignant melanocytic lesions 
The cytogenetic heterogeneity of the different subtypes of benign and malignant skin lesions 
were recently summarised by Blokx et al. [2010]. Some of the important DNA copy number 
alterations that distinguish melanomas from nevi can be successfully detected by interphase 
FISH [Bauer & Bastian, 2006; Gerami et al., 2010]. Based on previous array CGH 
observations, four DNA regions were selected, targeting 3 loci on chromosome 6 (MYB1: 
6q23, RREB1: 6p25 and centromere 6) and CCND1 on chromosome 11q13 as being the most 
powerful discriminators between melanomas and nevi that can assist in the diagnostic 
classification of melanocytic tumours that cannot be consistently classified by other 
currently available methods. The sensitivity of the four DNA probes was further tested by 
FISH in 110 nevi and 123 melanomas, and it was found that the overall sensitivity of the 
tested probes was 83%, and the specificity was 94% [Gerami et al., 2010]. In another study, 
the same group reported that copy number changes at 11q13 (CCND1) and 8q34 (harbouring 
the MYC oncogene) were highly associated with prognosis and could discriminate between 
metastasising and no metastasising melanomas [Gerami et al., 2011].  
The histopathologic subtypes of cutaneous melanomas (superficial spreading, nodular, acral 
lentiginous and lentigo maligna melanomas) are characterised based on the growth pattern 
of the radial growth phase of melanoma. Using interphase cytogenetics, several groups have 
showed that the different subtypes exhibit differences in chromosomal aberrations [Poetsch 
et al., 1998; Bastian et al., 2000; Treszl et al., 2004; Bastian et al., 2006] that may also 
contribute to distinct outcomes. Comparing the CGH profiles of AMs (acral melanomas) and 
SSMs, a significant difference was seen between the amplified loci/samples and between the 
two subtypes of melanomas. While all AMs exhibited at least one gene amplification, less 
than 15% of SSM samples showed amplification [Bastian, 2000]. The most frequently 
amplified region was 11q13, harbouring the CCND1 oncogene, which probably arises early 
in the progression of AM. The biological relevance of the CCND1 amplification was further 
investigated, and the results showed that CCND1 amplification was strongly correlated with 
protein expression and indicated that CCND1 is an oncogene involved in malignant 
melanoma [Bastian, 2002]. Recently, we reported that coamplification of CCND1 with other 
genes (especially TAOS1) within the 11q13 amplicon could contribute to a more aggressive 
phenotype than that of CCND1 alone [Lazar  et al., 2009]. 
Targeting a combination of these loci using FISH may become a useful standardised 
prognostic test for melanoma skin cancer in the future. However, it is important to note that 
FISH analysis should be performed in combination with standard clinical and 
histopathological evaluations [Gerami et al., 2010].  
3.1.2 New melanoma genes discovered by high-resolution array CGH 
A systematic analysis of the melanoma genome led to the discovery of a new lineage survival 
oncogene, MITF (3p14), which is amplified or shows copy number gains in 10% of primary 
and 15% to 20% of metastatic melanomas [Garraway et al., 2005]. Based on FISH analysis, 
the MITF copy number fluctuates between 4 and 13 copies per cell. However, no amplification 
can be detected in nevi samples. Comparing MITF copy number alterations and clinical 
parameters, it was found that patients presenting tissue carrying the amplified gene exhibited 
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survival of less than five years. A similar correlation was seen for MITF protein expression, 
which implicates MITF gene amplification in the progression and lethality of a subset of 
melanomas. It was clearly demonstrated that MITF plays a crucial role in melanocyte biology 
and melanoma progression [Hoek et al., 2008] and potentially acts as a dominant oncogene. 
MITF regulates the expression of a large variety of genes, including genes involved in 
pigmentation, cell cycle regulation, differentiation, survival and migration. In addition to 
amplification, altered MITF function during melanomagenesis can be achieved by single-
base substitutions or by mutation of its regulator, SOX10 [Cronin et al., 2009]. Targeting 
MITF in combination with BRAF or cyclin-dependent kinase inhibitors may offer a rational 
therapeutic opportunity to successfully treat this aggressive, chemoresistant disease.  
The discovery of new targets by array CGH was also reported by Gast et al. [2010]. In this 
study, SNP arrays with 250,000 targets were applied to 60 cell lines derived from 
metastasised melanomas. Amplifications were found to be more common than deletions in 
these cell lines. Similar to the findings of other studies, homozygous and heterozygous 
deletions of the CDKN2A gene were the most frequent type of deletion found at the 9p21 
locus, and these alterations were associated with a lack of gene expression. In addition to the 
common alterations described above, it was observed that melanoma cell lines without 
BRAF and NRAS oncogenic mutations exhibited losses of the entire 13q and 16q 
chromosome regions. These data further confirm that distinct molecular pathways are 
involved in malignant melanomas, driving melanoma initiation and progression in 
association with either oncogenic BRAF or NRAS mutations complemented mainly by the 
loss of tumour suppressor genes, including CDKN2A and PTEN. Alternatively, they may 
implicate the amplification of CCDN1 (11q13) and CDK4, together with deletions of the 13q 
and 16q chromosome arms, which contain two major players, the RB1 and MC1R genes 
respectively [Gast et al., 2010]. Losses of the entire chromosome 13q region have been 
predominantly observed in melanoma cell lines without BRAF and NRAS oncogenic 
mutations. Uncovering the potential role of the deletion of the q arms of both chromosomes 
13 and 16 requires further investigations in primary melanomas. 
A chromosome 6p gain is one of the most frequent alterations found in melanomas, as 
determined by CGH and classical cytogenetic studies. A novel melanoma metastasis gene 
on 6p25-p24 (NEDD9: neural precursor cell expressed, developmentally downregulated 9) 
showing recurrent focal amplification in 35% of human melanomas and melanoma cell lines 
was discovered by a cross-species comparison [Kim et al., 2006]. The expression of NEDD9 
is significantly upregulated relative to nontransformed melanocytes and benign melanocytic 
neoplasia, and this gene is overexpressed in 52% of melanomas, but only 14% of nevi. It was 
found that NEDD9 amplification and overexpression were strongly associated with 
enhanced invasion and metastasis formation related to malignant melanomas. The large 
regional gain on chromosome 6p and the high recurrence of the alteration likely indicate the 
presence and synergistic activities of multiple oncogenes on 6p, in addition to NEDD9. The 
observation that more than 50% of human primary melanomas exhibit higher NEDD9 
expression relative to benign nevi suggests the possibility that the amplification or 
overexpression of NEDD9 in a regional/focal manner may identify a subset of primary 
melanoma tumours with increased risk of metastasis [Kim et al., 2006]. 
4. Gene expression profiling of melanoma 
Molecular classification of cutaneous malignant melanoma by gene expression profiling was 
first described in 2000 [Bittner et al., 2000]. Based on the obtained gene expression data, two 
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major clusters were identified, but no correlation was found between the cluster groups and 
any clinical variable associated with their tumour sets. Another group investigated the 
relationship between the gene expression profiles and clinical outcomes of 58 primary 
melanomas; 254 genes were found whose expression might have a role in predicting the 
clinical outcome of melanoma patients [Winnepenninckx et al., 2006]. A study was recently 
conducted with the major aim of identifying new prognostic markers and therapeutic 
targets that might aid clinical cancer diagnosis and management [Jeffs et al., 2009]. Global 
transcript profiling identified a signature characterised by decreased expression of 
developmental and lineage specification genes, including MITF, EDNRB, DCT, and TYR, 
and increased expression of genes involved in interactions with the extracellular 
environment, such as PLAUR, VCAN, and HIF1a. Migration assays showed that the gene 
signature was correlated with the invasive potential of the cell lines, and external validation 
using publicly available data indicated that tumours with the invasive gene signature were 
less melanocytic and might be more aggressive. It is significant that the invasion signature 
could be detected in both primary and metastatic tumours, suggesting that gene expression 
conferring increased invasive potential in melanoma may occur independently of tumour 
stage [Jeffs et al., 2009].  
The impact of genomics on understanding human melanoma progression and metastasis 
was summarised by Ren et al. [2008]. Several groups have found distinct differences in gene 
expression patterns along the spectrum of melanoma tumour progression, with many 
showing distinct sets of over- and underexpressed genes that have been validated as having 
distinct, key roles in melanoma progression. Several research groups have attempted to 
develop large gene classifier sets composed of several hundreds or often thousands of genes. 
A critical analysis of gene expression studies relating to malignant melanoma progression 
was performed recently by Timár et al. [2010]. Despite the stunning success of genomics in 
defining genomic markers or gene signatures for breast cancer prognosis and for predicting 
therapies, there has been virtually no similar progress related to malignant melanoma. In 
summarising the microarray studies that have been performed on skin melanomas, it is 
noticeable that different groups used different microarray platforms in highly 
heterogeneous patient cohorts and pathological sample collections. Additionally, the 
investigated tumours may be heterogeneous even within a single study, containing 
sometimes limited numbers of primary melanomas or cutaneous, lymphatic or visceral 
metastases. Furthermore, the biological behaviour and histological appearance of the 
tumours were not taken into account in some studies, although some authors concluded 
that the gene expression signatures of superficial spreading and nodular melanomas are 
considerably different from each other [Jaeger et al., 2007]. Underlying the discrepancies in 
these data the problem is that the defined prognostic gene sets have not been validated in 
independent cohorts or datasets, with the exception of one study performed in primary 
tumours [Winnepenninckx et al., 2009]. 
The most recent systematic approach to characterise the spectrum of cancer-associated 
mRNA alterations through the integration of transcriptomic and structural genomic data 
has revealed new insights into melanoma biology and will likely lead to a new era of 
discovery in melanoma genomics that promises to reveal molecular mechanisms associated 
with the disease [Berger et al., 2010]. More than 700 non-synonymous coding variants have 
been identified. However, only a subset of these was validated to clarify whether they were 
bona fide somatic mutations. Based on the results described above, it is expected that most 
of these variants are inherited SNPs and that approximately 30% are somatic mutations. The 
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most interesting variants include a mutation observed in the melanoma cell line 501 Mel 
(CTNNB1, chr3:41241117, C/T), which was noted 135 times in the COSMIC database of 
somatic mutations in cancer. A new approach, paired-end massively parallel sequencing of 
cDNA, together with analyses of high-resolution chromosomal copy number data was used, 
as a result 11 novel melanoma gene fusions were identified, that produced by underlying 
genomic rearrangements and 12 novel read-through transcripts. These chimeric transcripts 
were mapped at base-pair resolution and traced to their genomic origins using matched 
chromosomal copy number information. Furthermore, these data were used to discover and 
validate base-pair mutations that accumulated in these melanomas, revealing a surprisingly 
high rate of somatic mutations and lending support to the notion that point mutations 
constitute the major driver of melanoma progression. Taken together, these results may 
indicate new avenues for target gene discovery related to melanoma, while also providing a 
template for large-scale transcriptome studies across diseases associated with many tumour 
types [Berger et al., 2010]. 
5. Epigenetic events: an explanation for altered gene expression in 
melanoma 
Over the past two decades, gene expression studies have revealed a relatively large number 
of genes that show altered expression at both the mRNA and protein levels. Despite some 
contradictory results that are probably due to the genetic variability and heterogeneity of 
primary melanomas, the altered expression of a group of transcripts can be affirmed to play 
a crucial role in the carcinogenesis and progression of melanomas. In addition to the success 
of mutation and copy number variation studies related to certain genes, the demonstration 
of gene deregulation has prompted scientists to explore other alterations that could be the 
cause of altered expression and that could further act as biomarkers for early diagnosis and 
represent a characteristic of less favourable clinical outcomes.  The commonly used term 
“epigenetics” has been rapidly spreading over the last decade. It emerged to define heritable 
changes in genome function that cannot be explained by direct influence over DNA 
sequences. As epigenetic mechanisms affect gene expression, resulting in different 
phenotypes without directly altering the underlying DNA sequence, it is reasonable that 
they should have an impact on cancer development. Because the importance of epigenetic 
processes in gene regulation is currently a topic of doubt and discussion, standard 
nomenclature for different types of epigenetic modifications is not available in the literature, 
although it is reasonable to distinguish between them based on the phase during which a 
specific event influences gene expression (Figure 3). There are two types of such alterations 
that are known to occur at the transcriptional level: DNA methylation and chromatin 
modification (post-transcriptional covalent change and chromatin rearrangement without 
chemical alteration). The third type of epigenetic alteration that has been discovered to date 
is RNA interference, which only affects a phenotype later, at the post-transcriptional level, 
as it directly cleaves mRNA, resulting in disrupted or no translation.  
5.1 DNA methylation 
5.1.1 Methyltransferases: potential epigenetic drug candidates  
The best described factor involved in epigenetic inheritance is DNA methylation, a covalent 
modification of cytosines (mainly at position 5, but also at position 4 or 6) that results in  
5-methyl-cytosine occurs in CpG dinucleotides that are part of CpG islands that can most 
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commonly be found at or near promoter regions in mammals. This process is accomplished 
through specific molecules: DNA methyltransferases (DNMTs), which are responsible for 
establishing and maintaining the unique methylation pattern on DNA. Three different types 
of DNMT have been reported to date. DNMT2 has rather low activity and functions only in 
tRNA methylation. DNMT1 and DNMT3 play essential roles in both mammalian 
development and in cancer biology, as they catalyse the addition of a methyl group to 
cytosines from the donor S-adenosyl-methionine. However, they require different substrates. 
Because DNMT1 is methylation dependent, it predominantly methylates hemimethylated 
CpGs. Therefore, DNMT1 is responsible for maintaining the methylation pattern, which is 
extremely important in cell division. DNMT3a and DNMT3b are referred to as de novo 
methylases because they act independently of previous methylation of the complementary 
strand. Both DNMT3a and DNMT3b could be important factors in establishing a new CpG 
methylation pattern, though DNMT3 exhibits a preference for centromeric regions  
[Cheng & Blumental, 2008]. Additionally, if a methyl group has already been  
 
 
Fig. 3. Main regulatory elements and pathways involved in the three main epigenetic 
mechanisms in melanoma. A: microRNA regulation at post-transcriptional level results in 
decreasing in gene expression. B: localised methylation occuring at the promoter regions 
attracts methyl-CpG-binding proteins to construct transcriptionally silent heterochromatin 
and cause direct downregulation of genes involved in various pathways. C: histone post-
transcriptional modifications alter gene expression of invasion and proliferation related 
molecules 
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added to a cytosine residue, methyl-CpG-binding proteins can attach to methylated regions. 
Therefore, a specific signature is constructed in assembling transcriptionally silent 
heterochromatin. It is widely accepted that DNA methylation of promoter regions, which 
are the main site of CpGs, can cause direct inactivation of specific genes [Howell et al., 2009; 
Sigalotti et al., 2010]. 
Because DNA methylation is described as a reversible mechanism, inhibition of promoter 
hypermethylation might represent the most promising therapeutic target for the treatment 
of melanoma. DNMT inhibitors are compounds that are able to demethylate 5-methyl-
cytosines by the direct obstruction of DNMT enzymes. To date, 3 types of DNMT inhibitors 
have been characterised. 1. Nucleoside analogues were the first of these inhibitors to be 
developed and include 5-azacitidine (Vidaza) and 5-aza-2'-deoxycytidine (Decitabin). The 
common feature of these two drugs is their incorporation into DNA strands; because they 
contain an amino group instead of carbon at the 5 position of cytosine, they cannot be 
methylated. Currently, both molecules are undergoing phase I or phase II clinical trials in 
combination with either interferon ǂ-2b or temozolomide. 2. Zebularine, a new type of 
nucleoside analogue, is less toxic compared to others because it does not contain an amino 
group. To date, only one study conducted on murine B16 melanoma has suggested a 
positive effect of Zebularine resulting in an increase in life span. 3. Non-nucleoside analogue 
DNMT inhibitors currently include procainamide and procaine. However, there are no data 
available related to their effect on melanoma. 4. Antisense oligonucleotides are substitute 
molecules for the DNMT1 enzyme (DNMT1 ASO), and they are currently undergoing 
preclinical drug testing [Howell et al., 2009; Sigalotti et al., 2010]. 
5.1.2 Localised hypermethylation 
Given the existence of relatively easy approaches that require even minute amounts of 
tumour DNA, there are currently substantial amounts of data available that refer to gene 
silencing associated with the localised CpG hypermethylation of a specific gene promoter. 
There are two options for investigating this epigenetic phenomenon: it can be estimated 
indirectly or measured directly. Indirect assessment consists of three steps: first, measuring 
mRNA or protein expression; next, treating samples with a specific drug that acts against 
the process of methylation, mainly by inactivating DNMT3a (see above); and finally, 
measuring gene expression again. Powerful arguments have been presented in the literature 
that support direct experiments as being less ambiguous; additionally, because treatment is 
only possible in cell lines, tumour tissues are not appropriate for this purpose. In spite of the 
existence of a large dataset that has revealed more than 80 genes downregulated by 
promoter methylation, to allow their clinical utilisation, the detected elements must be 
distinguished based on the number of primary tumour samples involved in the study and 
the frequency of positive results as eligibility criteria for diagnosis or to determine whether 
they are a candidate therapeutic target. Promoter hypermethylation of two molecules 
involved in the cell cycle, Ras association domain-containing protein 1 (RASSF1A) and the 
cyclin-dependent kinase inhibitor 2A-coding gene (CDKN2A), has been confirmed by 
multiple, substantive experiments; these findings have also been confirmed in melanoma 
cell lines [Furuta et al., 2004; Marini et al., 2006; Sigalotti et al., 2010]. A higher level of 
methylation of oestrogen receptor alpha (ERα) compared to normal tissues has also been 
revealed in both tumour specimens and cell lines [Furuta et al., 2004; Mori et al., 2006]. 
Gaining 5-methyl-cytosines in the promoter regions of suppressor of cytokine signalling 
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molecules (SOCS1 and SOCS2) has been demonstrated simultaneously with MGMT, which 
plays an essential role in DNA repair, and with TIMP3, which encodes a protein that 
protects the extracellular matrix from enzymatic degradation [Liu et al., 2008].  
Downregulation of RARB2 (retinoic acid receptor B2) has been validated in repeated studies: 
6 groups have investigated the methylation level of the RARB2 promoter, but their results 
are still inconsistent: some of these investigators have recorded high levels methylation in 
most of the examined specimens, while others have reported promoter methylation in only 
a few melanomas [Furuta et al., 2004; Liu et al., 2008]. One of the most remarkable studies 
concluded that PTEN methylation was a predictor for patient survival, even though it had 
not been associated with other clinical records. This study involved 230 primary melanomas 
[Lahtz et al., 2009]. 
In addition to the rapid progress that has been made in studying promoter 
hypermethylation at the single-gene level, only one group has attempted to conduct an 
array-based experiment, having chosen the most powerful and high-throughput bead array 
technology, to provide valuable information on the methylation pattern of the 1505 gene 
promoter. It is important to note that previous studies have given irrefutable proof of the 
reproducibility of this approach. It is regrettable that researchers have focused on only 
comparing the methylation level of primary invasive melanomas with benign melanocytes; 
therefore, no data are available on the methylation markers of diverse melanomas with 
different clinical behaviours. However, the findings of these investigators support the claim 
that a covalent change from cytosine to 5-methyl-cytosine in the promoter region occurs as 
an early aberration event in melanomas. The group’s results have clearly identified a group 
of genes in a statistically powerful interpretation that can be used to discriminate nevi from 
melanomas considering their methylation signature. Furthermore, they adapted this high-
throughput methylation profiling to FFPE samples, which are generally prepared by 
pathologists, abundantly available and appropriate for further routine screening [Conway et 
al., 2011]. 
5.1.3 Methylation patterns of cell-free DNA 
It is notable that efforts are now under way to develop methods to measure the methylation 
of genes in body fluids that are easy to obtain. Additionally, it is firmly believed that the 
methylation pattern of a specific gene in cell-free DNA (serum or urine) should resemble the 
markings of that gene in tumour tissue. Regarding early diagnosis, this represents a rapidly 
growing field, and a blood test aimed at quantifying tumour suppressor genes has already 
been made commercially available for colon cancer samples. Similar attempts have also been 
made in melanomas: hypermethylation of RASSF1A in serum has been demonstrated, 
although 3 conflicting publications have reported that it occurs to a lesser (19%) or a greater 
(63%) extent in melanomas [Furuta et al., 2004; Liu et al., 2008]. In serum, CDKN2A has also 
exhibited hypermethylation to a considerably higher level than in tumour tissues [Marini et 
al., 2006]. 
Because one of the most notable previous investigations demonstrated the prognostic 
relevance of PTEN methylation (as described above), studies were extended to quantify its 
methylation pattern in serum. A significant correlation was found between the methylation 
level of tumour tissue specimens and blood serum. Moreover, PTEN methylation might 
function as an early event in carcinogenesis, rather than a progression-related mechanism, 
based on experiments that compared the methylation levels of tumours and melanocytes 
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[Mirmohammadsadegh et al., 2006]. As it has been firmly demonstrated that PTEN silencing 
is due to an epigenetic event [Furuta et al., 2004], although it may have little impact on 
tumour progression, PTEN appears to be the most relevant candidate for the early diagnosis 
of melanoma by non-invasive tools. 
5.1.4 Genome-wide hypomethylation 
While most groups are studying extensively promoter-related hypermethylation, the 
importance of genome-wide demethylation or hypomethylation remains underestimated. 
However, these phenomena might also reflect important epigenetic alterations due to their 
ability to cause genetic instability. Genome-wide hypomethylation is characterised by the 
overall loss of 5-methyl-cytosines, which is believed to correspond to the loss of 
methylcytosines of repetitive transposable elements. During evolution, these elements 
integrated into the human genome and became protected from transcription due to their 
higher levels of methylcytosines. Considering the abundance of repetitive elements, it is 
clear why scientists generalise the loss of their 5-methyl-cytosine content to the ’whole 
genome’. Repetitive elements constitute 40% of the human genome and mainly consist of 
two different types: among SINE (short interspersed nucleotide element) sequences, only the 
Alu family is known, ranging from 400 to 500 bp, and it can be found in 105 copies across the 
human genome; LINE (long interspersed nucleotide element) sequences are longer than 5000 
to 6000 bp, and 104 copies of these elements are spread throughout the genome [Howell et 
al., 2009]. 
Investigations of demethylation in carcinogenesis have raised a crucial question: how can 
genome-wide hypomethylation contribute to genetic instability? As described above, the 
overall loss of 5-methyl-cytosines can be explained by the modification of repetitive 
elements exhibiting strong homology. As these elements are reactivated by hypomethylation, 
they can recombine with each other, causing karyotypic instability [Wild &Flanagan, 2010]. 
The cause of their demethylation remains in question, as current evidence is divided 
between two hypotheses: hypomethylation could be an important early cancer-causing 
aberration, or it might occur as a passive inconsequential side effect of carcinogenesis. Both 
theories have gathered supporting data. Based on animal experiments, DNMTs have a 
higher affinity for recognising and affecting damaged DNA; therefore, their normal function 
of maintaining methylation patterns during replication might fail, suggesting passive 
demethylation as a subsequent genetic alteration. For many years, it has been hypothesised 
that indirect proof of active demethylation is provided by the imprinting of gametes and 
early embryos, which undergo massive epigenetic reprogramming involving demethylation 
followed by remethylation [James et al., 2003; Wild & Flanagan, 2010]. Regrettably, studies 
on melanomas have been unable to give evidence of active demethylation. However, results 
from breast cancer studies are promising: oestrogen receptor-alpha-responsive genes show 
remarkable demethylation followed by remethylation under the influence of oestrogen 
treatment. These encouraging results might prompt scientists to extend their experiments to 
investigate the active demethylation of ERα-responsive elements in melanoma cell lines. As 
previous studies in melanoma have detected promoter hypermethylation of ERα, suggesting 
an important role of ERα epigenetics, in addition to hypermethylation, ERα might provide a 
significant contribution to the field of active demethylation [Méteiver et al., 2008]. 
To date the existence of genome-wide hypermethylation has been demonstrated in 16 
melanoma cell lines compared to melanocytes via repetitive elements. We are unable to 
conclude what the actual clinical effects of genome-wide methylation as the above-
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mentioned study focused only on comparing cell lines to controls, instead of drawing a 
demethylation-based distinction between cell lines with different characteristics. Our 
unpublished data also suggest a significant difference between normal tissues (nevus and 
skin) and melanoma specimens. However, aberrant hypomethylation may be the best 
marker for early diagnosis, as the results of a number of studies agree on the relevance of 
LINE hypomethylation in both cell lines and tissues [Tellez et al., 2009]. 
It is important to note that single-copy DNA regions can also feature hypomethylation, 
accompanied by mRNA and protein upregulation, as has been shown in colorectal, 
hepatocellular and breast cancers, although there is currently no evidence to suggest the 
same characteristics for melanomas. 
5.2 Histone modification and microRNA regulation of melanoma 
Eukaryotic DNA is packed into chromatin consisting of nucleosome units, each of which 
contains two copies of H2A, H2B, H3 and H4, as well as 146 bp of DNA. Each histone 
contains flexible N-terminal tails that can be a target for various post-translational 
modifications that determine the electrostatic power between DNA and histones and, 
therefore, contribute to determining transcriptionally active euchromatin or inactive 
heterochromatin. Histone modifications uniquely define the "histone code" that is read by 
multi-protein chromatin remodelling complexes to finally determine the transcriptional 
status of a target gene by modulating the chromatin compaction grade. While most studies 
rely on cell lines, there are preliminary results that show the importance of histone 
methylation in advance staged melanomas: a type of histone methyl-transferase (H3K27 
HMT EZH2) has been found to be upregulated in tumours, and as it has an inhibitory effect 
on the transcription of E-cadherin, it could contribute to invasion [O’Neill et al., 2001; 
Sigalotti et al., 2010]. In addition to histone methylation, losses of histone lysine acetylation 
have also been reported. The hypoacetylation-related suppression of CDKN1A/P21 and the 
pro-apoptotic proteins (APAF-1, BAX, BAK, BID, BIM, caspase 3 and caspase 8) have also 
been described in melanoma cell lines [Feinberg et al., 2006]. 
Another promising field of melanoma epigenetics is related to gene regulation by 
microRNAs (miRNAs). These are small, non-coding RNAs transcribed in the nucleus into 
primary transcripts, followed by further cleavage by a complex of Drosha and its cofactor 
into precursor miRNAs (pre-miRNAs). Pre-miRNAs are exported to the cytoplasm, where 
Dicer protein reduces them to short double strands, which are then incorporated into RNA-
induced silencing complexes that recognise target mRNA sequences, causing sequence-
specific degradation and thus impairing their translation.  
Only a single high-throughput experiment involving a relatively large set of samples has 
been performed on this topic [Levati et al., 2009]. However, the results of this study 
demonstrated inconsistency between cell lines and tumour tissues; moreover, the 
microarray results could not be confirmed by qPCR. Despite the high discrepancy in many 
cases, this group found that miRNA-205 and miRNA-23b were notably reduced, whereas 
miR-146a and miR-155 were upregulated only in tumour specimens compared to 
melanocytes and melanoma cell lines. Further functional studies have demonstrated the role 
of miRNA-155 in cell proliferation and survival [Levati et al., 2011]. 
Although strenuous efforts have been made to characterise the epigenetic changes involved 
in melanoma, studies have more often focused on elucidating alterations in DNA 
methylation than on estimating the functions of microRNAs and the realignment of histone 
molecules in melanomas. Despite the availability of a huge amount of data regarding 
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promoter-related hypermethylation, the function of this phenomenon related to progression 
is still controversial. Some experiments have shown that tumours associated with different 
clinical stages exhibit a characteristic methylation signature, while others have found that 
the patterns of 5-methyl-cytosine gains in promoter regions are rather homogeneous in 
melanomas, or exhibit minimal differences between various clinical subgroups of tumours. 
However, some studies have suggested that differential methylation patterns have a greater 
impact in driving melanocytic lesions to melanoma. According to the literature, the current 
state of our knowledge about genome-wide hypomethylation seems to be clearly outlined. 
Studies have already shown that hypomethylation of repetitive elements occurs as an early 
event in melanomas. Therefore, hypomethylation can offer a new facility that emphasises 
early detection in the case of applying a technical approach that may make rapid, systematic 
screening possible. 
Despite the strong progress in this field, it is still difficult to provide a concise summary 
about the importance of epigenetic changes in melanomas, although it can be asserted that 
promising findings will prompt further efforts in designing additional studies to obtain 
better insights into how melanoma progression is controlled by epigenetic events. Long-
term follow-ups of epigenetic drug treatments will be indispensable to characterise possible 
adverse effects of general demethylation. 
Finally, it should be noted that epigenetic mechanisms do not act separately but represent 
different utility in an integrated apparatus: the results of most recent studies indicate more 
challenges for the design of future experiments, as they have revealed that DNA 
methylation can influence histone modification to maintain altered gene expression, and 
miRNAs could also be a target of DNA methylation, besides representing a unique 
epigenetic mechanism. 
Although the genomic methods described above are mainly used in research laboratories, 
they are also employed in the clinical field as methods for patient selection in clinical trials 
and as predictive tests for the selection of treatments for some malignancies (e.g., Oncotype 
DX; Genomic Health, Redwood City, CA; MammaPrint, Agendia, Amsterdam, 
Netherlands). Integration of genomic datasets from different platforms, such as gene copy 
number and expression profiling data, represents a powerful method for the identification 
of functionally relevant molecular aberrations. However, genomic techniques do not 
supplant more targeted analytical methods. The complementary use of both of these 
approaches will be essential to identify and exploit molecular changes in cancer for 
improved diagnosis and treatment.  
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